Breast Cancer Clinical Trial Using Lapatinib and Herceptin

- The folks at Dana-Farber Cancer Institute are studying the effects of Lapatinib; Herceptin on Breast Cancer in individuals ages 18 years and older. This clinical trial is slated to start May 2007 and is expected to end circa December 2014.

617-632-3800
Nancy Lin, MD
Overall Study Contact Info
StatusName Contact Phone
RecruitingNancy Lin, MDnlin@partners.org617-632-3800

This study is officially titled, "A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer."

Locations

Baylor College of Medicine

Houston, Texas - Active, not recruiting

Vanderbilt University

Nashville, Tennessee - Active, not recruiting

University of North Carolina

Chapel Hill, North Carolina - Active, not recruiting

Mayo Clinic

Rochester, Minnesota - Active, not recruiting

Dana-Farber at Faulkner Hospital

Boston, Massachusetts - Active, not recruiting

Beth Israel Deaconess Medical Center

Boston, Massachusetts - Recruiting

Dana-Farber Cancer Institute

Boston, Massachusetts - Recruiting

University of Chicago

Chicago, Illinois - Active, not recruiting

University fo Alabama at Birmingham

Birmingham, Alabama - Active, not recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.